Revelation Biosciences, Inc.
REVB· Nasdaq
Released May 8, 2025, after the close
10-Q filed May 8, 2025, 38 days after period end · 0000950170-25-066897
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Income | -$2.05M | -$2.68M | $6.16M | -$6.62M |
| EPS Diluted | -$25.34 | -$39.37 | $37.07 | -$15.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR